Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson B, Dahl O, Rosencher N, Kurth A, et al. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson B, Dahl O, Rosencher N, Kurth A, et al.
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Full medication coverage is expected to increase patient compliance from 50% to 76%. Expanded coverage would cost insurers an average of $644 more per patient, but would avert an average…  
  • Assuming that Medicare Part D covers about 37% of beneficiaries’ drug costs, it is estimated that providing post-myocardial infarction Medicare beneficiaries with full coverage for combination pharmcotherapy will save more…  
  • Since 1950, reduction in heart disease mortality has added more than 3 1/2 years to the expected lifetimes of both men and women.  
  • The projected economic value of eliminating deaths from heart disease is approximately $48 trillion.